A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma (Q43106634)
Jump to navigation
Jump to search
scientific article published in August 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma |
scientific article published in August 2010 |
Statements
1 reference
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma (English)
1 reference
1 reference
Micaela Hernberg
1 reference
Meri-Sisko Vuoristo
1 reference
Kristiina Tyynelä
1 reference
Marjut Laukka
1 reference
Seppo Pyrhönen
1 reference
1 August 2010
1 reference
1 reference
20
1 reference
4
1 reference
318-325
1 reference
Identifiers
1 reference
1 reference